AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02981316 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX7455
Description: Microbiota capsule(s) given twice daily in the morning, and in the evening.
Study NCT03940924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: High Intensity Interval Training + Resistance Training (HIIT + RT)
Study NCT02036593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk Your Heart to Health
Description: Walking group sessions conducted 3 times per week for 32 weeks.
Study NCT02036593 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Walk Your Heart to Health
Description: Walking group sessions conducted 3 times per week for 32 weeks.
Study NCT01005719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid
Description: Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
Study NCT01005719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
Study NCT01368341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 1 tablet, 100 mg, b.i.d. 14 days
Study NCT01567241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical hypnosis or relaxation music
Description: 25 minute tape recording
Study NCT01567241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clinical hypnosis or relaxation music
Description: 25 minute tape recording
Study NCT02105155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion at day 7 ± 3 Prograf® to Advagraf®
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
Study NCT02105155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conversion at day 90±5 Prograf® to Advagraf®
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
Study NCT03020719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Glutathione
Description: Oral Glutathione oral powder
Study NCT03020719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral powder
Study NCT03492658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
Study NCT03492658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
Study NCT03492658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
Study NCT04157478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
Study NCT04157478 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
Study NCT04157478 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
Study NCT04157478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Study NCT04157478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Study NCT01055028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV every 21 days x 6 cycles.
Study NCT01055028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle
Study NCT05406973 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SBK microkeratome versus femtosecond laser in flap creation
Description: prospective comparative non randomized interventional clinical study
Study NCT00529295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
Study NCT00529295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
Study NCT01798602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin or identical placebo
Description: Tablet crushed for administration via feeding tube
Study NCT01798602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo for rosuvastatin
Study NCT02071615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg tablet given once by mouth
Description: 3-arm, single-drug dosage comparison study
Study NCT02930343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
Study NCT02930343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
Study NCT02930343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
Study NCT02930343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
Study NCT02930343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Study NCT02930343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
Study NCT04473638 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Deltoid Repair
Description: . A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
Study NCT00449813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg Pantoprazole
Study NCT01087684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser trabeculoplasty
Description: Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
Study NCT01087684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
Study NCT02414919 — intervention group
Intervention type: DRUG
Intervention: Mirena (Levonorgestrel IUS, BAY86-5028)
Description: Levonorgestrel-releasing intrauterine device 20 mcg/day
Study NCT02414919 — intervention group
Intervention type: DRUG
Intervention: ParaGard
Description: Copper T380A
Study NCT02414919 — intervention group
Intervention type: DRUG
Intervention: Implanon/Nexplanon
Description: Etonorgestrel contraceptive implant
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screening for Complications
Description: To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glycaemic control assessment
Description: Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glycaemic control assessment
Description: Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QoL assessment
Description: For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003).
Study NCT04750382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008+Cisplatin+Gemcitabine
Description: Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
Study NCT02423993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QoL assessment
Description: For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003).
Study NCT02389192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZMAPP
Description: ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
Study NCT02657629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Feeding Regimen
Description: Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
Study NCT02657629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Bolus Feeding Regimen
Description: Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
Study NCT06126536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crestal Maxillary Sinus Floor Elevation using Osseodensification
Description: Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.
Study NCT06126536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Maxillary Sinus Floor Elevation
Description: A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
Study NCT00516503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen/amitriptyline/ketamine gel
Description: Applied topically
Study NCT00516503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin 90 mg/m2 iv
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2 iv
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 600 mg/m2 iv
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 iv
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)
Description: Max. 3 months.
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)
Description: Max. 3 months.
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)
Description: Max. 3 months
Study NCT02909751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol 300 mg x 3 daily
Description: Max. 6 months
Study NCT02260739 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study NCT04919759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-Basic
Description: Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
Study NCT02321748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast
Study NCT02321748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151
Study NCT04312776 — intervention group
Intervention type: OTHER
Intervention: none intervention
Study NCT02678624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment according to the Collabri model
Description: The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
Study NCT03669562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Liposome for Injection
Description: intravenous infusion Alprostadil Liposome
Study NCT03669562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion liposome control
Study NCT04127058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iloperidone
Description: Oral Tablet
Study NCT00377455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
Study NCT00377455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
Study NCT02509780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vichy
Description: Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
Study NCT02794064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-modal imaging
Description: This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
Study NCT02962674 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: prostaFix System
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (IP)
Description: Induction phase (Week 0-8) (IP) - Placebo IV group
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 1mg/kg (IP)
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 3 mg/kg (IP)
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg (IP)
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
Study NCT00771667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV - Responder - Placebo SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16